<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148744</url>
  </required_header>
  <id_info>
    <org_study_id>XmAb7195-01</org_study_id>
    <nct_id>NCT02148744</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xencor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xencor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled,
      ascending dose study to investigate the safety, tolerability, and pharmacokinetics of
      XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 21, 2015</completion_date>
  <primary_completion_date type="Actual">September 21, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events including type and severity</measure>
    <time_frame>Date of randomization up to Day 43</time_frame>
    <description>Number, type and severity of adverse events, vital signs, electrocardiogram (ECGs), laboratory tests, and physical examinations will be reported during the study from randomization up to Day 43</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events including type and severity of a priming IV dose followed by an escalating second IV dose</measure>
    <time_frame>Date of randomization up to Day 36</time_frame>
    <description>Number, type and severity of adverse events, vital signs, electrocardiogram (ECGs), laboratory tests, and physical examinations will be reported during the study from randomization up to Day 36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of XmAb7195 and blood levels of human anti-human antibodies after single-dose IV administration of XmAb7195</measure>
    <time_frame>Time of dosing up to Day 43</time_frame>
    <description>Pharmocokinetic (PK) analysis for levels of XmAb7195 will be determined in subjects blood from time of initial dosing up to Day 43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentration of XmAb7195 and blood levels of human anti-human antibodies after a priming IV dose followed by an escalating second IV dose of XmAb7195</measure>
    <time_frame>Time of dosing up to Day 36</time_frame>
    <description>Presence of human anti-human antibodies will be assessed from time of dosing up to Day 36</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Allergic Conjunctivitis</condition>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>XmAb7195 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>XmAb7195</intervention_name>
    <description>Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8</description>
    <arm_group_label>XmAb7195 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>XmAb7195 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males and females 18 to 50 years of age

          -  Parts 1 and 3: Healthy subjects with no clinically significant abnormality identified
             on medical or laboratory evaluation and no history of any clinically significant
             disorder, condition, or disease that would pose a risk to subject safety or interfere
             with the study evaluation, procedures, or completion;

          -  Part 2: Otherwise healthy male and female subjects with a history of allergic rhinitis
             and/or allergic conjunctivitis and/or atopic dermatitis with an elevated serum IgE

          -  Subjects who are able and willing to give written informed consent;

          -  Subjects who have the ability to complete all study assessments;

          -  Subjects who are willing to forego other forms of experimental treatment during the
             study.

        Exclusion Criteria:

          -  Subjects who have a clinically relevant history or presence of respiratory,
             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, connective tissue diseases, or disorders (other than allergic rhinitis
             and/or conjunctivitis and/or atopic dermatitis in Part 2) that would pose a
             significant risk to subject safety or significantly interfere with the study
             evaluation, procedures, or completion

          -  Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody and/or human immunodeficiency virus (HIV) Type I or Type II tests at
             Screening;

          -  Subjects who do not agree to use medically acceptable methods of contraception (as
             defined in the protocol);

          -  Subject is pregnant or breast feeding, or planning to become pregnant within 3 months
             of administration of XmAb7195;

          -  Subjects who have used any investigational drug in any clinical trial within 8 weeks
             prior to admission (Day -1), or have used an experimental monoclonal antibody;

          -  Subjects with prior exposure to a monoclonal antibody;

          -  Subjects with a history of anaphylaxis;

          -  Subjects who have received live vaccines ≤ 3 months from Screening;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel Baltimore Early Phase Clinical Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel Baltimore Early Phase Clinical Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

